Compare Moderna, Inc. (MRNA) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs State Street SPDR S&P Homebuilders ETF — how do they compare? Moderna, Inc. trades at $63.62 (market cap $24.18B), while State Street SPDR S&P Homebuilders ETF trades at $108.31. The key difference: Moderna, Inc. is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | XHB | |
|---|---|---|
Market Cap | $24.18B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $81.80 | $121.36 |
52-Week Low | $22.36 | $94.86 |
Enterprise Value | $20.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
XHB trades at $108.35 with a slight 0.1% daily gain, showing bullish technical momentum with strong moving average support. The ETF benefits from positive housing market developments including new home sales growth and supportive legislation, though mixed economic data creates uncertainty. Technical indicators show overall bullish sentiment with 14 buy signals versus 3 sell signals.
The outlook remains cautiously optimistic as housing affordability legislation and seasonal demand provide tailwinds, but high mortgage rates and record home prices pose headwinds. Key risks include interest rate sensitivity and economic volatility, while institutional positioning suggests selective confidence in the homebuilding sector's recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
